Propelling: The Sky’s the Limit with LiDAR Technology

 

The LiDAR technology market’s expected growth is up to USD 2.2 billion by 2024, according to Markets & Markets. The adoption of Lidar systems in UAVs is a contributing factor to this expanding growth. Chuck Dorgan, Microdrone’s Director of Sales for the Americas, and Sebastien Long, Microdrone’s Canada & US Sales manager, shared their perspectives on the LiDAR boom with host Daniel Litwin.

“LiDAR sensors are getting smaller and smaller,” Long said, “And, worldwide, more and more companies are offering sensors.”

But with so many different LiDAR sensor products on the market, certain factors make a difference. The type of data gathered by the sensors and the LiDAR sensor workflow can be a product differentiator, Long said. And one of the issues Long often sees with so many choices is that a lot of first-time users don’t understand how to use the technology or make the right choice.

Microdrones has a customer care team in place to help clients out, something many other providers in this industry do not have. This piece of the LiDAR/UAV integration puzzle, both Long and Dorgan said, is essential for full product integration.

“We don’t want our clients to be left on the side after they purchased one of our systems,” Long said. “We want to be able to help them with any issue or question they may have.”

Because Microdrones owns their entire LiDAR workflow and created a complete, integrated solution, Dorgan said this helps early adopters and people new to the technology.

“The better the integration, the easier the workflow gets for every client,” Long said.

The workflow Microdrones provides helps clients achieve the results they want to get out of their UAV system.

With so much excitement around the possibilities of LiDAR technology, what does the future hold for the UAV industry? Long said sensors will get smaller and lighter, the software will improve, and Microdrones will be on the lookout for integrating the best of this technology as it becomes available.

For the latest news, videos, and podcasts in the Software & Technology Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!
Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More